Cargando…
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4
BACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem ce...
Autores principales: | McClements, Lana, Annett, Stephanie, Yakkundi, Anita, O’Rourke, Martin, Valentine, Andrea, Moustafa, Nermeen, Alqudah, Abdelrahim, Simões, Bruno M., Furlong, Fiona, Short, Amy, McIntosh, Stuart A., McCarthy, Helen O., Clarke, Robert B., Robson, Tracy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460676/ https://www.ncbi.nlm.nih.gov/pubmed/30975104 http://dx.doi.org/10.1186/s12885-019-5500-0 |
Ejemplares similares
-
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer
por: Annett, Stephanie, et al.
Publicado: (2019) -
Role of the Hsp90 cochaperone, FKBPL, in oestrogen receptor signalling and breast cancer growth and survival
por: McKeen, H, et al.
Publicado: (2008) -
FKBPL Is a Critical Antiangiogenic Regulator of Developmental and Pathological Angiogenesis
por: Yakkundi, Anita, et al.
Publicado: (2015) -
The Anti-Migratory Effects of FKBPL and Its Peptide Derivative, AD-01: Regulation of CD44 and the Cytoskeletal Pathway
por: Yakkundi, Anita, et al.
Publicado: (2013) -
FKBPL: a marker of good prognosis in breast cancer
por: Nelson, Laura, et al.
Publicado: (2015)